Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
1.170
-0.010 (-0.85%)
At close: May 30, 2025, 4:00 PM
1.200
+0.030 (2.56%)
After-hours: May 30, 2025, 7:24 PM EDT
Allogene Therapeutics Stock Forecast
Stock Price Forecast
According to 9 professional analysts, the 12-month price target for Allogene Therapeutics stock ranges from a low of $4.00 to a high of $14. The average analyst price target of $8.44 forecasts a 621.37% increase in the stock price over the next year.
Price Target: $8.44 (+621.37%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Allogene Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 3 | 3 | 3 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 10 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $8 → $4 | Strong Buy | Maintains | $8 → $4 | +241.88% | May 15, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $14 → $10 | Strong Buy | Maintains | $14 → $10 | +754.70% | May 14, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $9 → $7 | Buy | Maintains | $9 → $7 | +498.29% | May 14, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $10 | Buy | Reiterates | $10 | +754.70% | May 14, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $10 → $9 | Buy | Maintains | $10 → $9 | +669.23% | May 14, 2025 |
Financial Forecast
Revenue This Year
16.69K
from 22.00K
Decreased by -24.15%
Revenue Next Year
18.36K
from 16.69K
Increased by 10.02%
EPS This Year
-1.15
from -1.32
EPS Next Year
-1.03
from -1.15
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 105,000 | 105,000 | 147.2M | ||
| Avg | 16,687 | 18,360 | 48.9M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 377.3% | 529.2% | 801,751.9% | ||
| Avg | -24.1% | 10.0% | 266,212.6% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.85 | -0.67 | -0.87 | ||
| Avg | -1.15 | -1.03 | -1.24 | ||
| Low | -1.53 | -1.75 | -2.12 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.